Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial-Reference-Cited by-同舟云学术

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Published:2020-11-05 Issue:4 Volume:35 Page:919-927
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Warren R.B.¹,Carrascosa J.M.²^ORCID,Fumero E.³,Schoenenberger A.³,Lebwohl M.G.⁴,Szepietowski J.C.⁵^ORCID,Reich K.⁶^ORCID

Affiliation:

1. Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre The University of Manchester Manchester UK

2. Department of Dermatology Germans Trias i Pujol University Hospital (HUGTP) Autonomous University of Barcelona (UAB) Badalona Spain

3. Almirall R&D Barcelona Spain

4. Icahn School of Medicine at Mount Sinai New York NY USA

5. Department of Dermatology, Venereology and Allergology Wroclaw Medical University Wroclaw Poland

6. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing Skinflammation^® Center University Medical Center Hamburg‐Eppendorf Hamburg Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16964

Reference21 articles.

1. Psoriasis

2. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

3. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks

4. How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis

5. Clinical studies in dermatology require a post-treatment observation phase to define the impact of the intervention on the natural history of the complaint

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis;Biomolecules;2024-05-03

2. Inflammatory Memory in Chronic Skin Disease;JID Innovations;2024-05

3. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension;Chinese Medical Journal;2024-01-09

4. The biological basis of disease recurrence in psoriasis;Italian Journal of Dermatology and Venereology;2023-08

5. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation;Clinical Drug Investigation;2023-07